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Shock And Acute Myocardial Infarction – Results From The PL-ACS Registry
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Mateusz Tajstra1, Lukasz Pyka1, Marian Zembala1, Krzysztof Strojek1,
Lech Polonski1
1Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland
Background: The aim was to compare treatment and clinical outcomes of cardiogenic
shock (CS) AMI patients with and without diabetes mellitus.
Methods: We analyzed 896 patients with CS and AMI from PL-ACS registry.
Follow-up mortality was obtained from the government database.
Results: Patients with diabetes comprised 23% of CS AMI pts and they were of higher
risk proﬁle. Treatments and outcomes are show in the table and ﬁgure.Diabetes mellitus
N=204 (23%)
No diabetes
mellitus
N=692 (77%) P value
Mean age,
years  SD
70  11 67  13 0.0029
Female sex, % 47 36 0.0061
History chronic renal
disease, %
16 7 0.0002
History of chronic
pulmonary disease, %
9 4 0.0082
History of prior
myocardial infarction,
%
21 14 0.017
STEMI, % 71 77 0.074
Primary PCI, % 61 57 0.25
Bypass surgery
(CABG), %
3 3 0.88
Left ventricle ejection
fraction, %
37  11 37  14 0.77
In-hospital major
bleeding, %
9 9 0.99
In-hospital stroke, % 2,9 1,5 0.26
In-hospital mortality, % 37 48 0.0056
30-day mortality, % 48 59 0.0040
2-year mortality, % 64 69 0.21Conclusions: Early mortality in cardiogenic shock is lower in patients with diabetes
mellitus however after 2 years there is no signiﬁcant difference between diabetic and
non-diabetic patients. Mortality reduction with invasive treatment is similar in patients
with and without diabetes.
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A Pathologic Study of Explanted Parachute Devices from Seven Heart Failure
Patients following Percutaneous Ventricular Restoration
Fumiyuki Otsuka1, Elena Ladich1, Renu Virmani1
1CVPath Institute, Inc., Gaithersburg, MD
Background: The Parachute (CardioKinetix Inc., Menlo Park, CA) partitions the
left ventricle excluding the scarred myocardium from functioning myocardium, and
has shown promise in clinical studies as an adjunctive interventional treatment for
heart failure (HF). We sought to evaluate the pathologic ﬁndings of the percutaneous
Parachute device implanted in patients with severe HF.
Methods: We have examined histopathologically 7 cases (6 males [age 43-74 years;
mean 56 years] and one female [55 years]) of Parachute device that were eitherB136 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jretrieved at autopsy (n¼4) or during transplantation (n¼3); implant duration, 15 to
1,533 days.
Results: Three patients died of cardiac causes and none died from complications.
Histologic early changes (<30 days, n¼1) included adherent thrombus, with focal
neutrophil inﬁltration and degenerating inﬂammatory cells. Over time (31 to 300 days,
n¼4) there was organized thrombus and development of neoendocardial thickening
especially at the free-edge of the device and its contact with the adjacent endocardium
while the base of the device showed varying degrees of ﬁbrin thrombus. The greatest
organization of thrombus was observed in devices removed at >300 days (680 and
1533 days) (Figure); both had fractures of the foot along with strut fracture and one
had tearing of the ePTFE.
Conclusions: The percutaneous Parachute device appears as a promising adjunctive
treatment for patients suffering from severe HF. The pathologic changes are those of
organizing thrombus with and without inﬂammation with minor complications of foot
and strut fracture.TCT-442
Predictors of mortality in patients with acute myocardial infarction complicated
by cardiogenic shock: Can we improve outcomes by proper timing of mechanical
circulatory support?
Gert Richardt1, Bettina Schwarz1, Mohamed Abdel-Wahab1
1Heart Center, Segeberger Kliniken, Bad Segeberg, Germany
Background: Cardiogenic shock remains a serious complication of acute myocardial
infarction (AMI). Mechanical support with intra-aortic balloon pump (IABP) after
revascularization has recently failed to improve outcomes. We sought to determine
predictors of in-hospital mortality and develop a clinical risk score for shock patients
with AMI enrolled in our institutional shock registry.
Methods: One hundred and two consecutive patients with cardiogenic shock due to
AMI treated with primary percutaneous coronary intervention (PCI) and IABP-
support were analyzed. Univariate and multivariate logistic regression analysis was
used to identify independent predictors of in-hospital mortality. Logistic regression
analysis and receiver-operating characteristic curve were used to generate a mortality
score.
Results: The mean age was 70.111.4 years; 70% were males. One third (32.4%)
had a non-ST segment elevation myocardial infarction and 30.4% were resuscitated
before PCI. Mean left ventricular ejection fraction was 24.710.6%, 59.8% of
patients received vasopressors and 22.5% developed acute renal failure. In 52% of
patients IABP therapy was initiated after primary PCI, while the remaining patients
had an IABP-assisted primary PCI. In-hospital mortality was 40.2%. Using multi-
variate analysis, age (odds ratio [OR] 1.08, 95% conﬁdence interval [CI] 1.02-1.15),
resuscitation before PCI (OR 3.46, 95%CI 1.03-11.62), vasopressor use (OR 7.88,
95%CI 2.01-30.88), acute renal failure (OR 11.18, 95%CI 2.71-46.07) and IABP-
implantation after PCI (OR 4.36, 95%CI 1.39-13.62) were independently associated
with in-hospital mortality. Based on these predictors a mortality-risk score was
calculated as follows: 1.5 x IABP-Timing (before PCI ¼ 0; after PCI ¼1) + 0.1 x
(age) + resuscitation before PCI (no ¼ 0; yes ¼ 1) + 2 x vasopressor use (no ¼ 0; yes
¼ 1) + 2.5 x acute renal failure (no ¼ 0; yes ¼ 1). Using a cut-off value of 10.4, this
score had a speciﬁcity of 83% and a sensitivity of 82% for prediction of in-hospital
death.
Conclusions: The timing of IABP insertion was the only modiﬁable factor predicting
in-hospital mortality in our cohort. This point deserves consideration when inter-
preting the results of IABP trials.TCT Abstracts/POSTER/Circulatory Support, Heart Failure, and HOCM
